Alkeon Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alkeon Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-204,484	Closed	-$18.7M	–	55
2016 Q2	$18.7M	Sell	204,484 -99,730	-33%	-$8.48M	0.36%	49
2016 Q1	$25.1M	Sell	304,214 -85	-0%	-$6.92K	0.52%	43
2015 Q4	$31.9M	Hold	304,299	–	–	0.65%	40
2015 Q3	$31.1M	Hold	304,299	–	–	0.65%	41
2015 Q2	$41.6M	Buy	304,299 +25,000	+9%	+$3.1M	0.81%	44
2015 Q1	$34.8M	Sell	279,299 -446,876	-62%	-$47.3M	0.66%	41
2014 Q4	$65.6M	Sell	726,175 -656,600	-47%	-$54.6M	1.28%	33
2014 Q3	$99.8M	Sell	1,382,775 -150,000	-10%	-$9.86M	1.98%	21
2014 Q2	$95.4M	Buy	1,532,775 +81,275	+6%	+$4.91M	1.74%	24
2014 Q1	$99M	Buy	1,451,500 +450,000	+45%	+$33.2M	1.67%	24
2013 Q4	$70.5M	Buy	+1,001,500	New	+$68M	1.19%	33

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Alkeon Capital Management's BMRN Position: Q3 2016 in Review

Alkeon Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2016, closing a stake of 204,484 shares — an estimated $18.7M sold.

Alkeon Capital Management first reported a position in BMRN in Q4 2013 and held it in 11 quarters. The position peaked at $99.8M in Q3 2014. 422 funds tracked by Wall St. Rank hold BMRN as of Q3 2016.

Alkeon Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Alkeon Capital Management sold 204,484 BioMarin Pharmaceuticals shares in Q3 2016, an estimated $18.7M.
Alkeon Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 11 quarters.
Alkeon Capital Management's BioMarin Pharmaceuticals position peaked at $99.8M in Q3 2014.
422 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2016.

Based on Alkeon Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.